TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.

TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.

Tumor necrosis factor alpha (TNF) is capable of inducing regression of solid tumors. However, TNF released in response to Toll-like receptor 4 (TLR4) activation by bacterial lipopolysaccharide (LPS) is the key mediator of cytokine storm and septic shock that can cause severe tissue damage limiting a...

Full description

Bibliographic Details
Main Authors: Gary J Haderski, Bojidar M Kandar, Craig M Brackett, Ilia M Toshkov, Christopher P Johnson, Geraldine M Paszkiewicz, Venkatesh Natarajan, Anatoli S Gleiberman, Andrei V Gudkov, Lyudmila G Burdelya
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0227940

Internet

https://doi.org/10.1371/journal.pone.0227940

Similar Items